AML Drug Is Next Big Thing For Seattle Genetics

Seattle Genetics' "next opportunity for a commercial product" – following on from the success of its Takeda-partnered Hodgkin's lymphoma drug Adcetris (brentuximab vedotin) – will move into Phase III trials in 2016.